Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Rating) insider Stephen K. Brannan sold 5,000 shares of Karuna Therapeutics stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $216.00, for a total value of $1,080,000.00. Following the completion of the sale, the insider now directly owns 15,000 shares in the company, valued at $3,240,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Karuna Therapeutics Stock Up 1.9 %
Shares of NASDAQ:KRTX opened at $231.67 on Friday. The company has a market capitalization of $7.96 billion, a price-to-earnings ratio of -30.57 and a beta of 1.18. Karuna Therapeutics, Inc. has a 52 week low of $92.26 and a 52 week high of $278.25. The firm has a 50 day moving average of $225.26 and a 200 day moving average of $173.01.
Hedge Funds Weigh In On Karuna Therapeutics
A number of large investors have recently made changes to their positions in KRTX. IFP Advisors Inc acquired a new position in shares of Karuna Therapeutics in the 3rd quarter valued at $35,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Karuna Therapeutics in the 3rd quarter valued at $72,000. Lazard Asset Management LLC acquired a new position in shares of Karuna Therapeutics in the 1st quarter valued at $87,000. Dupont Capital Management Corp acquired a new position in shares of Karuna Therapeutics in the 3rd quarter valued at $96,000. Finally, Nisa Investment Advisors LLC increased its position in shares of Karuna Therapeutics by 11.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 766 shares of the company’s stock valued at $97,000 after acquiring an additional 80 shares during the period.
Analyst Ratings Changes
About Karuna Therapeutics
Karuna Therapeutics, Inc, a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis.
- Get a free copy of the StockNews.com research report on Karuna Therapeutics (KRTX)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
Receive News & Ratings for Karuna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karuna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.